EpiPen Price Increases Were Made Worse by the Fact That You Can’t Buy Just One
September 7, 2016
By: Emma Court
MarketWatch
Axinn partner Thomas Rohback was quoted in the Market Watch article, "EpiPen Price Increases Were Made Worse by the Fact That You Can’t Buy Just One."
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
IBA Annual Conference 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
Antitrust 101: Trial-Minded Antitrust Discovery
Webinar
Antitrust
ABA Antitrust Plaintiffs' Roundtable 2025
Speaking Engagement
Antitrust
Centerforce IP Strategy Summit: Palo Alto
Speaking Engagement
Intellectual Property
Corporate Counsel Women, Influence, & Power in Law Conference 2025
Speaking Engagement
Antitrust